| Literature DB >> 32290558 |
Adriana Mika1,2, Alicja Pakiet1, Aleksandra Czumaj2, Zbigniew Kaczynski3, Ivan Liakh2, Jarek Kobiela4, Adrian Perdyan5, Krystian Adrych6, Wojciech Makarewicz7, Tomasz Sledzinski2.
Abstract
Recent evidence suggests that lipid composition in cancer tissues may undergo multiple alterations. However, no comprehensive analysis of various lipid groups in colorectal cancer (CRC) tissue has been conducted thus far. To address the problem in question, we determined the contents of triacylglycerols (TG), an energetic substrate, various lipids necessary for cell membrane formation, among them phospholipids (phosphatidylcholine, phosphatidylethanolamine), sphingolipids (sphingomyelin) and cholesterol (free, esterified and total), and fatty acids included in complex lipids. 1H-nuclear magnetic resonance (1H-NMR) and gas chromatography-mass spectrometry (GC-MS) were used to analyze the lipid composition of colon cancer tissue and normal large intestinal mucosa from 25 patients. Compared with normal tissue, cancer tissues had significantly lower TG content, along with elevated levels of phospholipids, sphingomyelin, and cholesterol. Moreover, the content of oleic acid, the main component of TG, was decreased in cancer tissues, whereas the levels of saturated fatty acids and polyunsaturated fatty acids (PUFAs), which are principal components of polar lipids, were elevated. These lipidome rearrangements were associated with the overexpression of genes associated with fatty acid oxidation, and the synthesis of phospholipids and cholesterol. These findings suggest that reprogramming of lipid metabolism might occur in CRC tissue, with a shift towards increased utilization of TG for energy production and enhanced synthesis of membrane lipids, necessary for the rapid proliferation of cancer cells.Entities:
Keywords: cancer cell proliferation; cell membrane; colorectal cancer; lipid oxidation; lipids; nuclear magnetic resonance; polyunsaturated fatty acids
Year: 2020 PMID: 32290558 PMCID: PMC7230725 DOI: 10.3390/jcm9041095
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Biochemical and clinical characteristics of the study subjects. SEM—standard error of the mean; BMI—body mass index; CRP-hs—high-sensitivity C-reactive protein; HDL—high density lipoprotein; LDL—low density lipoprotein; T stage—tumor stage; UICC stage—Union for International Cancer Control stage.
| Parameter | Mean ± SEM |
|---|---|
| Age (years) | 69.8 ± 2.66 |
| BMI (kg/m2) | 28.4 ± 1.09 |
| CRP-hs (mg/L) | 3.53 ± 0.737 |
| Total serum cholesterol (mg/dL) | 155 ± 12.7 |
| Triacylglycerols (mg/dL) | 123 ± 11.2 |
| HDL (mg/dL) | 36.7 ± 2.57 |
| LDL (mg/dL) | 99.2 ± 8.44 |
| Glucose (mg/dL) | 105 ± 8.53 |
| Albumin (g/dL) | 3.11 ± 0.186 |
| Total protein (g/dL) | 6.10 ± 0.331 |
| Stroma content in tumor (%) | 22.9 ± 2.42 |
| Connective tissue cells content in tumor (%) | 15.1 ± 2.22 |
| Inflammatory cells content in tumor (%) | 7.79 ± 1.72 |
| Epithelial cells content in tumor (%) | 59.5 ± 4.51 |
| Tumor-stroma ratio | 5.36 ± 0.577 |
|
|
|
| Sex | |
| Male | 16 |
| Female | 9 |
| Location of primary tumor | |
| Cecum | 9 |
| Ascending colon | 3 |
| Transverse colon | 2 |
| Descending/proximal sigmoid colon | 4 |
| Rectosigmoid | 3 |
| Rectum | 4 |
| T stage | |
| T1 | 2 |
| T2 | 9 |
| T3 | 12 |
| T4 | 2 |
| UICC stage | |
| I | 10 |
| II | 3 |
| III | 9 |
| IV | 3 |
| Lymph node status | |
| N0 | 13 |
| N1/N2 | 12 |
Figure 1Representative photographs of normal large intestinal mucosa (A) and colorectal cancer tissue (B) after hematoxylin-eosin stain, original magnification: 10×.
Figure 2Total lipid content in normal and colorectal cancer tissue. Values are mean ± SEM; ** p < 0.01, n = 25.
Figure 3PLS-DA scores scatter plots obtained for normal and cancer tissue 1H-NMR spectra (A) and GC-MS analysis (B); n = 25.
Intensities of signals for various lipid groups obtained during 1H-NMR spectroscopic analysis.
| L.p. | 1H NMR signal | Chemical Shift * | Normal Colon Tissue | Colon Cancer Tissue |
|
|---|---|---|---|---|---|
| 1 | -C18 | 0.70 | 79.6 ± 6.93 | 141 ± 10.9 | <0.001 |
| 2 | -C26H3/-C27 | 0.86 | 199 ± 13.8 | 256 ± 17.8 | 0.004 |
| 3 | -C21 | 0.93 | 167 ± 17.2 | 221 ± 16.1 | 0.011 |
| 4 | -C19 | 1.02 | 96.5 ± 9.25 | 150 ± 14.1 | <0.001 |
| 5 | -C19 | 1.04 | 48.0 ± 11.9 | 58.4 ± 5.82 | 0.424 |
| 6 | -C | 0.89 | 1813 ± 71.8 | 1444 ± 101 | <0.001 |
| 7 | -(C | 1.27 | 7444 ± 321 | 6315 ± 441 | 0.013 |
| 8 | CHC | 1.32 | 4810 ± 221 | 3078 ± 236 | <0.001 |
| 9 | -CO-C | 2.32 | 1139 ± 49.3 | 769 ± 57.2 | <0.001 |
| 10 | -CO-CH2C | 1.61 | 1272 ± 62.2 | 892 ± 70.0 | <0.001 |
| 11 | -HC= | 5.36 | 725 ± 42.1 | 551 ± 71.4 | 0.028 |
| 12 | -C | 2.02 | 1013 ± 51.4 | 618 ± 52.9 | <0.001 |
| 13 | -C | 2.08 | 205 ± 17.0 | 163 ± 24.4 | 0.146 |
| 14 | CHC | 2.78 | 58.7 ± 7.21 | 40.7 ± 7.90 | 0.106 |
| 15 | -CO-C | 2.42 | 17.3 ± 1.44 | 21.8 ± 2.44 | 0.049 |
| 16 | CHC | 2.84 | 66.8 ± 14.2 | 144 ± 30.7 | 0.022 |
| 17 | -CH2-C | 3.11 | 17.7 ± 2.41 | 46.0 ± 5.08 | <0.001 |
| 18 | C2 | 3.26 | 15.3 ± 1.85 | 27.3 ± 3.94 | 0.007 |
| 19 | -N+(C | 3.21 | 84.6 ± 7.53 | 141 ± 10.3 | <0.001 |
| 20 | -C | 3.62 | 92.8 ± 6.76 | 161 ± 13.3 | <0.001 |
| 21 | -C | 4.25 | 97.0 ± 8.87 | 139 ± 13.7 | 0.005 |
| 22 | -C | 3.22 | 177 ± 71.8 | 1139 ± 338 | <0.001 |
| 23 | -N+(C | 3.68 | 255 ± 23.7 | 495 ± 40.6 | <0.001 |
| 24 | >C3 | 4.01 | 171 ± 18.2 | 309 ± 27.2 | <0.001 |
| 25 | -C2 | 5.24 | 38.3 ± 3.28 | 71.1 ± 7.43 | <0.001 |
| 26 | >C1 | 4.33 | 334 ± 20.9 | 137 ± 17.4 | <0.001 |
| 27 | -C2 | 5.28 | 134 ± 10.0 | 41.6 ± 6.11 | <0.001 |
| 28 | >C1 | 4.16 | 368 ± 21.0 | 210 ± 18.7 | <0.001 |
* Chemical shift for proton or protons in bold. PE—phosphatidylethanolamines; PL—phospholipids; SM—sphingomyelin; PC—phosphatidylcholines; TG—triacylglycerols.
Figure 4Intensities of NMR signal for selected groups of lipids: (A) triacylglycerols; (B) free cholesterol; (C) phospholipids; (D) phosphatidylethanolamines; (E) sphingomyelin; (F) phosphatidylcholines; values are mean ± SEM; ** p < 0.01 *** p < 0.001, n = 25.
Contents (% of total FA) of main FAs and FA groups in normal and colorectal cancer tissue.
| Fatty Acids | Normal | Cancer Tissue |
|
|---|---|---|---|
| 16:0 | 22.0 ± 0.368 | 20.7 ± 0.318 | 0.017 |
| 18:0 | 7.14 ± 0.467 | 12.5 ± 0.567 | <0.001 |
|
|
|
|
|
| 16:1 | 4.86 ± 0.353 | 3.34 ± 0.201 | <0.001 |
| 18:1 | 45.0 ± 0.953 | 35.6 ± 1.07 | <0.001 |
|
|
|
|
|
| 18:2 (LA) | 11.1 ± 0.398 | 11.2 ± 0.399 | 0.682 |
| 20:4 (ARA) | 2.99 ± 0.349 | 6.73 ± 0.500 | <0.001 |
|
|
|
|
|
| 18:3 (ALA) | 0.040 ± 0.004 | 0.050 ± 0.007 | 0.012 |
| 20:5 (EPA) | 0.210 ± 0.025 | 0.450 ± 0.041 | <0.001 |
| 22:6 (DHA) | 0.450 ± 0.044 | 1.02 ± 0.059 | <0.001 |
|
|
|
|
|
a Upregulated; b downregulated. Values are mean ± SEM. Bold represents main groups of fatty acids.
Figure 5Relative expression levels of selected genes in normal and colorectal cancer tissue. Values are mean ± SEM; * p < 0.05, n = 25; CPT1a—Carnitine palmitoyltransferase I; HMGCR—HMG-CoA reductase; PCYT1A—choline-phosphate cytidylyltransferase A; PISD—phosphatidylserine decarboxylase; SMS1 - sphingomyelin synthase 1; SMS2; sphingomyelin synthase 2.